Ferner RE. Hazards, risks and reality. Br J Clin Pharmacol. 1992. https://doi.org/10.1111/j.1365-2125.1992.tb04013.x.

Article  PubMed  PubMed Central  Google Scholar 

Royal Society Study Group. Risk assessment. London: The Royal Society; 1983.

Google Scholar 

Aronson JK. Adjusting therapeutic dosage regimens to optimise the balance of benefit to harm. Clin Med (Lond). 2005. https://doi.org/10.7861/clinmedicine.5-1-16.

Article  PubMed  Google Scholar 

Montgomery (Appellant) v Lanarkshire Health Board (Respondent) (Scotland). 11 March 2015. https://www.supremecourt.uk/cases/uksc-2013-0136.html. Accessed 7 Apr 2024.

Smith RL. The Paton Prize Award: the discovery of the debrisoquine hydroxylation polymorphism: scientific and clinical impact and consequences. Toxicology. 2001. https://doi.org/10.1097/00008571-199111000-00013.

Article  PubMed  Google Scholar 

Juhaeri J. Benefit-risk evaluation: the past, present and future. Ther Adv Drug Saf. 2019. https://doi.org/10.1177/2042098619871180.

Article  PubMed  PubMed Central  Google Scholar 

Coplan PM, Noel RA, Levitan BS, Ferguson J, Mussen F. Development of a framework for enhancing the transparency, reproducibility and communication of the benefit-risk balance of medicines. Clin Pharmacol Ther. 2011. https://doi.org/10.1038/clpt.2010.291.

Article  PubMed  Google Scholar 

US Food and Drug Administration. Benefit–risk assessment in drug regulatory decision-making 2018: draft PDUFA VI implementation plan (FY 2018-2022). Rockville, MD: U.S. Department of Health and Human Services, Food and Drug Administration, 2018. https://www.fda.gov/media/112570/download. Accessed 6 Feb 2024.

Kürzinger ML, Douarin L, Uzun I, El-Haddad C, Hurst W, Juhaeri J, et al. Structured benefit-risk evaluation for medicinal products: review of quantitative benefit-risk assessment findings in the literature. Ther Adv Drug Saf. 2020. https://doi.org/10.1177/2042098620976951.

Article  PubMed  PubMed Central  Google Scholar 

Hughes D, Waddingham E, Mt-Isa S, Goginsky A, Chan E, Downey GF, et al. PROTECT Benefit-Risk Group. Recommendations for benefit-risk assessment methodologies and visual representations. Pharmacoepidemiol Drug Saf. 2016. https://doi.org/10.1002/pds.3958.

Article  PubMed  Google Scholar 

Grabias B, Kumar S. Adverse neuropsychiatric effects of antimalarial drugs. Expert Opin Drug Saf. 2016. https://doi.org/10.1080/14740338.2016.1175428.

Article  PubMed  Google Scholar 

Gogtay NJ, Ferner RE. Mefloquine for malarial prophylaxis in military personnel. BMJ. 2015. https://doi.org/10.1136/bmj.h5797.

Article  PubMed  Google Scholar 

Aronson JK. "Collaborative care” is preferable to “patient centred care. BMJ. 2016. https://doi.org/10.1136/bmj.i2926.

Article  PubMed  PubMed Central  Google Scholar 

World Health Organization (WHO). Antibiotic resistance. 31 July 2020. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance. Accessed 6 Feb 2024.

Medicines and Healthcare products Regulatory Agency (MHRA). Patient involvement strategy. 2021. https://www.gov.uk/government/publications/patientinvolvement-strategy. Accessed 6 Feb 2024.

European Medicines Agency. Stakeholders and Communication Division. The patient’s voice in the evaluation of medicines. 18 October 2013 EMA/607864/2013. https://www.ema.europa.eu/en/documents/report/report-workshop-patients-voice-evaluation-medicines_en.pdf. Accessed 6 Feb 2024.

Cashin AG, Wand BM, O’Connell NE, Lee H, Rizzo RRN, Bagg MK, et al. Pharmacological treatments for low back pain in adults: an overview of Cochrane reviews. Cochrane Database Systc Rev. 2023. https://doi.org/10.1002/14651858.CD013815.pub2.

Article  Google Scholar 

Makary MA, Overton HN, Wang P. Overprescribing is major contributor to opioid crisis. BMJ. 2017. https://doi.org/10.1136/bmj.j4792.

Article  PubMed  Google Scholar 

Islam A, Butler T, Nath SK, Alam NH, Stoeckel K, Houser HB, et al. Randomized treatment of patients with typhoid fever by using ceftriaxone or chloramphenicol. J Infect Dis. 1988. https://doi.org/10.1128/AAC.37.8.1572.

Article  PubMed  Google Scholar 

Pullar T, Wright V, Feely M. What do patients and rheumatologists regard as an ‘acceptable’ risk in the treatment of rheumatic disease? Br J Rheumatol. 1990. https://doi.org/10.1093/rheumatology/29.3.215.

Article  PubMed  Google Scholar 

Aronson JK, Derry S, Loke YK. Assessing perceptions of benefit and harm of common drug therapies using therapeutic scenarios. Br J Clin Pharmacol. 2003;55(4):438.

Google Scholar 

Aronson JK, Ferner RE. Biomarkers: a general review. Curr Protoc Pharmacol. 2017. https://doi.org/10.1002/cpph.19.

Article  PubMed  Google Scholar 

Hingorani AD, Windt DA, Riley RD, Abrams K, Moons KG, Steyerberg EW, et al. PROGRESS Group. Prognosis research strategy (PROGRESS) 4: stratified medicine research. BMJ. 2013. https://doi.org/10.1136/bmj.e5793.

Article  PubMed  PubMed Central  Google Scholar 

Kent DM, Paulus JK, van Klaveren D, D’Agostino R, Goodman S, Hayward R, et al. The predictive approaches to treatment effect heterogeneity (PATH) statement. Ann Intern Med. 2020. https://doi.org/10.7326/M18-3667.

Article  PubMed  Google Scholar 

Report of the Committee of Principal Investigators. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Lancet. 1984;2(8403):600–4.

Google Scholar 

Aronson JK, Ferner RE. Clarification of terminology in drug safety. Drug Saf. 2005. https://doi.org/10.2165/00002018-200528100-00003.

Article  PubMed  Google Scholar 

Ferner R, Aronson J. Susceptibility to adverse drug reactions. Br J Clin Pharmacol. 2019. https://doi.org/10.1111/bcp.14015.

Article  PubMed  PubMed Central  Google Scholar 

Campagna JD, Bond MC, Schabelman E, Hayes BD. The use of cephalosporins in penicillin-allergic patients: a literature review. J Emerg Med. 2012. https://doi.org/10.1016/j.jemermed.2011.05.035.

Article  PubMed  Google Scholar 

Køster-Rasmussen R, Korshin A, Meyer CN. Antibiotic treatment delay and outcome in acute bacterial meningitis. J Infect. 2008. https://doi.org/10.1016/j.jinf.2008.09.033.

Article  PubMed  Google Scholar 

Moran R, Devchand M, Smibert O, Trubiano JA. Antibiotic allergy labels in hospitalized and critically ill adults: a review of current impacts of inaccurate labelling. Br J Clin Pharmacol. 2019. https://doi.org/10.1111/bcp.13830.

Article  PubMed  PubMed Central  Google Scholar 

Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, et al. PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008. https://doi.org/10.1056/NEJMoa0706135.

Article  PubMed  Google Scholar 

Evans DA, Manley KA, McKusick VA. Genetic control of isoniazid metabolism in man. BMJ. 1960. https://doi.org/10.1136/bmj.2.5197.485.

Article  PubMed  PubMed Central  Google Scholar 

Gutiérrez-Virgen JE, Piña-Pozas M, Hernández-Tobías EA, Taja-Chayeb L, López-González ML, Meraz-Ríos MA, et al. NAT2 global landscape: genetic diversity and acetylation statuses from a systematic review. PLoS One. 2023. https://doi.org/10.1371/journal.pone.0283726.

Article  PubMed  PubMed Central  Google Scholar 

Lennard L, Cartwright CS, Wade R, Richards SM, Vora A. Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia. Br J Clin Pharmacol. 2013. https://doi.org/10.1111/bcp.12066.

Article  PubMed  Google Scholar 

Relling MV, Schwab M, Whirl-Carrillo M, Suarez-Kurtz G, Pui CH, Stein CM, et al. Clinical Pharmacogenetics Implementation Consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update. Clin Pharmacol Ther. 2019. https://doi.org/10.1002/cpt.1304.

Article  PubMed  Google Scholar 

Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, et al. Medical genetics: a marker for Stevens–Johnson syndrome. Nature. 2004. https://doi.org/10.1038/428486a.

Article  PubMed  PubMed Central  Google Scholar 

Lonjou C, Thomas L, Borot N, Ledger N, de Toma C, LeLouet H, et al. RegiSCAR Group. A marker for Stevens–Johnson syndrome: ethnicity matters. Pharmacogenom J. 2006. https://doi.org/10.1038/sj.tpj.6500356.

Article  Google Scholar 

Camacho Arroyo MT, Rivas Paterna AB, Meneses Monroy A, Cabrera García L, Blázquez González P, Mancebo Salas N, et al. Off-label and unlicensed drug use in a pediatric intensive care unit of a tertiary care Spanish hospital: a descriptive study. Arch Argent Pediatr. 2023. https://doi.org/10.5546/aap.2021-02550.eng.

Article  PubMed  Google Scholar 

Tang L, Zhao K, Hou N. Off-label use of antimicrobials among hospitalized children: a retrospective study of 3,406 patients. Front Microbiol. 2023. https://doi.org/10.3389/fmicb.2023.1173042.

Article  PubMed  PubMed Central  Google Scholar 

Bateman DN, Rawlins MD, Simpson JM. Extrapyramidal reactions with metoclopramide. Br Med J (Clin Res Ed). 1985. https://doi.org/10.1136/bmj.291.6500.930.

Article  PubMed  Google Scholar 

Martin RM, Biswas PN, Freemantle SN, Pearce GL, Mann RD. Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies. Br J Clin Pharmacol. 1998. https://doi.org/10.1046/j.1365-2125.1998.00817.x.

Article  PubMed  PubMed Central  Google Scholar 

Zucker I, Prendergast BJ. Sex differences in pharmacokinetics predict adverse drug reactions in women. Biol Sex Differ. 2020. https://doi.org/10.1186/s13293-020-00308-5.

Article  PubMed  PubMed Central